Fecal Transplants Increase Peanut Tolerance in Adults, Study Finds

A single fecal microbiota transplant (FMT) can significantly increase peanut tolerance in adults with severe allergies, according to a phase 1 clinical trial led by Boston Children's Hospital. The findings suggest that altering the gut microbiome may provide a more rapid and durable path to allergen tolerance than existing treatment methods.

The trial involved 15 participants, aged 18 to 33, who initially reacted to 100 mg of peanut protein or less. Six participants in total showed improved tolerance. In the group receiving FMT alone, three out of 10 responded, while three out of five participants in the group receiving antibiotic pretreatment followed by FMT showed improvement. This indicates that antibiotic pretreatment may have improved the response rate from 30% to 60%.

The Science of Tolerance

Researchers sourced donor stool from OpenBiome to facilitate the transplants. The study observed a distinct shift in the immune profiles of the responders, who showed an increase in regulatory T cells associated with immune tolerance and a corresponding reduction in T-helper cells associated with allergic reactions.

Dr. Rima Rachid, director of the Allergen Immunotherapy Program at Boston Children's Hospital, noted that a single FMT led to a significant increase in the threshold of reactivity to peanut at both one and four months after treatment. This indicates that the effect of the microbiome shift was prolonged, rather than a temporary fluctuation in sensitivity.

Shifting the Treatment Paradigm

For adults with life-threatening food allergies, options have historically been limited. While oral immunotherapy (OIT) is an established approach, it typically requires six months of rigorous, incremental treatment to achieve similar levels of tolerance. This research builds on preclinical mouse studies that demonstrated bacteriotherapy could prevent food allergies by modifying the gut microbiome.

If these results are validated in larger trials, the approach could lead to a new class of "Microbial Transplantation Therapy" (MTT). Such a system would be significantly easier to administer than the months-long commitment required by OIT and could potentially offer a more effective solution for those with severe sensitivities.

Future Outlook

While the results are encouraging, the study remains a phase 1 trial with a small sample size. Future research will need to determine the optimal antibiotic pretreatment protocol and confirm the long-term safety and efficacy of FMT across a broader demographic of allergic adults. For now, the study provides a proof-of-concept that the gut-immune axis can be manipulated to reduce the severity of food allergies.